EP 167: From Myosin Inhibitors to Sarcomere Modulators: The Next Era in HCM Care

About this episode

In this episode of Parallax, Dr Ankur Kalra welcomes Dr Anjali Tiku Owens, Associate Professor of Medicine and Director of the Hypertrophic Cardiomyopathy Center at the University of Pennsylvania, for an in-depth discussion on one of the greatest unmet needs in hypertrophic cardiomyopathy (HCM): the treatment of symptomatic non-obstructive HCM. Together, they explore the complex pathophysiology driving symptoms in these patients, the limitations of traditional therapies, and the evolving understanding of chronotropy, inotropy and lusitropy in clinical decision-making. Dr Owens also shares insights from recent clinical trial data presented at ESC Congress 2025, highlighting emerging sarcomere-targeted therapies, including aficamten and the investigational agent EDG-7500. The conversation examines how these novel approaches may reshape treatment paradigms, improve functional capacity and address longstanding therapeutic gaps for patients with non-obstructive HCM, while offering a preview of where the field may be headed next. Questions and comments can be sent to "podcast@radcliffe-group.com" and may be answered by Ankur in the next episode. Host: @AnkurKalraMD and produced by: @R